Klotho is a mammalian senescence-suppression protein that has homology with glycosidases. The extracellular domain of Klotho is secreted into urine and blood and may function as a humoral factor. Klotho-deficient mice have accelerated aging and imbalance of ion homeostasis. Klotho treatment increases cell-surface abundance of the renal epithelial Ca 2؉ channel TRPV5 by modifying its N-linked glycans. However, the precise sugar substrate and mechanism for regulation by Klotho is not known. Here, we report that the extracellular domain of Klotho activates plasma-membrane resident TRPV5 through removing terminal sialic acids from their glycan chains. Removal of sialic acids exposes underlying disaccharide galactose-N-acetylglucosamine, a ligand for a ubiquitous galactoside-binding lectin galectin-1. Binding to galectin-1 lattice at the extracellular surface leads to accumulation of functional TRPV5 on the plasma membrane. Knockdown of ␤-galactoside ␣2,6-sialyltransferase (ST6Gal-1) by RNA interference, but not other sialyltransferases, in a human cell line prevents the regulation by Klotho. Moreover, the regulation by Klotho is absent in a hamster cell line that lacks endogenous ST6Gal-1, but is restored by forced expression of recombinant ST6Gal-1. Thus, Klotho participates in specific removal of ␣2,6-linked sialic acids and regulates cell surface retention of TRPV5 through this activity. This action of Klotho represents a novel mechanism for regulation of the activity of cell-surface glycoproteins and likely contributes to maintenance of calcium balance by Klotho.
T
he Klotho gene was identified from a mouse strain in which mutation of the gene causes multiple phenotypes closely resembling human aging, including shortened life span, infertility, muscle and skin atrophy, pulmonary emphysema, osteopenia, hyperphosphatemia, and vascular and soft tissue calcification (1) . The encoded protein, Klotho, is a single-pass transmembrane protein with a large extracellular domain (952 aa in human), a membrane-spanning segment, and a short (11 aa) intracellular carboxyl terminus (1) . Overexpression of Klotho extends life span in mice, supporting that Klotho is an aging-suppression molecule (2) . The role of Klotho in human aging is suggested by reports that polymorphisms of KLOTHO are correlated with life span, osteoporosis, and coronary artery disease in humans (3) (4) (5) .
The biological function of Klotho and how deficiency of Klotho contributes to aging-associated phenotypes remains elusive. Klotho is predominantly expressed in distal renal tubules, parathyroid glands, and epithelial cells of the choroids plexus (1, 2, 6) . The extracellular domain of Klotho is shed extracellularly (in urine, blood, and cerebrospinal fluid) and elicits biological effects on target cells (2, 7, 8) , suggesting that it functions as a circulating hormone. With respect to the mechanism of hyperphosphatemia, recent studies report that both full-length Klotho and Klotho ectodomain bind to multiple FGF receptors and increase their affinity for FGF23 (9, 10) . FGF23 is a circulating hormone that decreases serum phosphate levels by suppressing renal phosphate reabsorption. These findings underscore that Klotho Ϫ/Ϫ mice and
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Ϫ/Ϫ mice share many phenotypes, including hyperphosphatemia (11) . To support an important role of Klotho in the regulation of mineral metabolism in humans, Ichikawa et al. (12) recently reported that a mutation in KLOTHO causes severe tumoral calcinosis in a young girl.
The extracellular domain of Klotho is composed of two internal repeats, KL1 and KL2, each sharing amino acid sequence homology to family 1 glycosidases (1, 13) . Recently, Chang et al. (14) reported that Klotho treatment increases cell-surface abundance of the renal epithelial Ca 2ϩ channel TRPV5 by modifying its N-linked glycans. However, the precise sugar substrate for Klotho and how modification of glycans by Klotho increases surface expression of TRPV5 proteins are not known. Here, we report that Klotho ectodomain increases surface abundance of TRPV5 through mediating and removing terminal sialic acids from their glycan chains. Removal of sialic acids exposes underlying disaccharide N-acetyllactosamine (LacNAc), a ligand for galectin-1. Binding to galectin-1 at the extracellular surface leads to accumulation of functional TRPV5 on the plasma membrane. This action of Klotho represents a novel mechanism for regulation of the activity of cell-surface glycoproteins and likely contributes to the maintenance of calcium homeostasis by Klotho.
Results

The Extracellular Domain of Klotho Participates in Removal of Sialic
Acids from N-Glycans of TRPV5, Causing Its Retention at the Cell Surface. Sialic acid (N-acetylneuraminic acid) residues often cap the terminal galactose residues of glycoproteins (15) . We tested the hypothesis that Klotho increases surface abundance of TRPV5 by hydrolyzing terminal sialic acid residues of the glycan chains. The abundance of functional TRPV5 channels at the cell surface was examined by measuring whole-cell current density in transfected HEK cells (16) (Fig. 1A) . The extracellular domain of Klotho (KLe) likely functions as a humoral factor (2, 7, 8) . Incubation of TRPV5-transfected cells with purified recombinant murine KLe for Ϸ16-24 h increased TRPV5 current density dose-dependently (Fig. 1 A) . The median effective concentration (EC 50 ) for KLe is Ϸ50 pM. Mutation of a single N-linked glycosylation site, Asn-358, to glutamine (N358Q) prevented the regulation of TRPV5 by Klotho (Fig. 1 A) , supporting the notion that Klotho modifies an N-glycan of TRPV5 (14) . A sialidase from Clostridium perfringens had similar effects on TRPV5 (Fig. 1B) . The effect of bacterial sialidase was not additive to that of Klotho. A specific inhibitor of sialidase, 2-deoxy-2,3-dehyro-N-acetylneuraminic acid (DANA) (17) , prevented the effect of Klotho (Fig. 1C ) and bacterial sialidase (data not shown).
The effects of Klotho and bacterial sialidase on surface abun-dance of TRPV5 were confirmed by biotinylation assays. Cellsurface biotinylated TRPV5 proteins consist of glycosylated (indicated by ''Gly'') and underglycosylated forms (14) (Fig. 1D) , likely because TRPV5 exists as a tetramer in the plasma membrane (18) and glycosylation of subunits is heterogeneous. Consistent with the results of whole-cell current density, Klotho and the bacterial sialidase each increased the surface abundance of WT TRPV5 but not of N358Q mutant (Fig. 1D) . DANA prevented this effect. No detectable shift in migration for KLe-or Siad-treated TRPV5 was observed (in low-exposure films; data not shown), which is consistent with the idea that only limited number of sugar residues (such as terminal sialic acids) are removed by treatment with KLe or sialidase. Together, these results are consistent with the hypothesis that Klotho controls surface expression of TRPV5 via removal of sialic acids from glycan chains. Mutations including Asn-241, Glu-416, and Glu-691 in the putative active sites of mouse Klotho (13, 19) abolished the activity that increases TRPV5 currents (Fig. 1E) . Thus, one or more of these residues are essential for regulating the channels. We further examined the effect of Klotho in the physiological urinary pH (Ϸ6.4) and found that the regulation of TRPV5 by Klotho was enhanced in extracellular pH 6.4 relative to that in pH 7.4 (Fig. 1F) . The critical role of Klotho in regulating TRPV5 was further confirmed by using neutralizing antibodies against Klotho (20) [see supporting information (SI) Text and Fig. S1 ].
Klotho Increases Surface Abundance of TRPV5 by Decreasing Its
Endocytosis. Next, we investigated the mechanism for increase of the surface abundance of TRPV5 by Klotho. We recently found that TRPV5 undergoes constitutive dynamin-dependent endocytosis (unpublished results). Interference of endocytosis by a dominant-negative dynamin (K44A rat dynamin II) increased baseline TRPV5 current and prevented an increase of current by Klotho ( Fig. 2A) . These results suggest that Klotho decreases dynamindependent retrieval of TRPV5 channels, allowing them to accumulate at the cell surface. Consistent with its effect on surface abundance of the channel, we found that Klotho did not affect single-channel open probability or single-channel conductance of TRPV5 (data not shown). Moreover, Klotho did not increase TRPV5 currents within 30 min (Fig. 2B ). The increase in TRPV5 currents, however, could be detected after Ն3 h of incubation with Klotho (Fig. 2B ). To exclude that the delayed increase in currents is caused by a slow activity of Klotho, TRPV5-transfected cells were incubated with Klotho for 15-60 min, followed by extensive washing to remove Klotho in the medium and further incubation in a Klotho-free medium for 16-24 h. We found that incubation with Klotho for 15 min was sufficient to cause an increase of TRPV5 current measured at Ն16 h later (Fig. 2C ). These results are consistent with the idea that Klotho increases surface abundance of TRPV5 by decreasing endocytosis of the channels. The delay in increase of TRPV5 after treatment by Klotho may be related to the rate of endocytosis of TRPV5 and/or the interaction between TRPV5 and galectin-1 (see below).
Removal of Terminal Sialic Acids from N-Glycans of TRPV5 Exposes
Underlying LacNAc for Binding to Galectin-1. Removal of sialic acids from typical complex-type asparagine-linked glycans exposes terminal LacNAc (15) (Fig. 3A) , which is a ligand for galectins.
Galectins are a family of galactoside-binding animal lectins (21) . Many galectins are secreted and interact with proteins at the extracellular surface. We examined the role of galectin binding in mediating the effect of Klotho on ion channels. HEK cells express multiple galectins, including galectin-1, galectin-8, and galectin-9 ( Fig. S2 A) . Galectin-1 is ubiquitously expressed (21) . Knockdown of galectin-1, but not of galectin-8 and galectin-9, prevented the increase of TRPV5 by Klotho (Fig. S2B ). Extracellular application of an antibody against galectin-1, but not galectin-8, after treatment with Klotho prevented the increase of TRPV5 (Fig. 3B ). Galectin-1 binds LacNAc and ␣2,3-sialylated LacNAc, but not ␣2,6-sialylated LacNAc (22) . Extracellular application of LacNAc and ␣2,3-sialylated LacNAc, but not ␣2,6-sialylated LacNAc, blocked the effects of Klotho (Fig. 3C) . Coimmunoprecipitation experiments show that galectin-1 interacted with TRPV5 only after treatment with Klotho (Fig. 3D) . As controls, galectin-1 did not interact with a glycosylation-defective TRPV5 mutant, N358Q. Thus, binding with galectin-1 is N-glycan-mediated and is essential for the Klotho-induced cell-surface retention of ion channels. The increase in TRPV5 currents was prevented by removing terminal galactose by application of ␤-galactosidase (an exo-galactosidase) simultaneously with Klotho, but not before Klotho (Fig. 3E) . These results show that Klotho-mediated removal of terminal sialic acids and exposure of underlying galactose is essential for galectin-1 binding to TRPV5.
␣2,6-Linked Sialic Acid Is the Target for Klotho. Sialyltransferases catalyze the transfer of sialic acid residues from the activated donor cytidine monophosphate-sialic acid to acceptor glycoproteins or glycolipids via either ␣2,3, ␣2,6 or ␣2,8 glycosidic linkage (named ST3, ST6, and ST8, respectively) (23, 24) . To identify which sialic acid linkage is the target for Klotho, we knocked down expression of individual sialyltransferase by RNA interference. Because interference of N-glycan modification may affect forward trafficking of cell membrane proteins (25), we analyzed the relative increase of currents by Klotho in each RNAi experiment. Knockdown of all five ST6s by pooled RNAi, but not of all six ST3s or all five ST8s, prevented the increase of TRPV5 by Klotho (Fig. 4A) . There are five members of human ST6s, each with unique oligosaccharide substrate specificity (23, 24) . Among these ST6s, ST6Gal-1 is ubiquitously expressed and catalyzes the transfer of sialic acids via ␣2-6-linkage to galactose residues of galactose␤1-4N-acetylglucosamine (24) . Knockdown of ST6Gal-1, but not the other ST6s, prevented the effect of Klotho on TRPV5 (Fig. 4B) , indicating that ST6Gal-1 is responsible for the synthesis of sialic acid substrate for Klotho. Additionally, we confirmed that Klotho had no effects on TRPV5 in CHO cells that contain endogenous ST3s but not ST6s (26) (Fig. 4C ). Forced expression of recombinant ST6Gal-1, but not of ST3Gal-1, conferred the regulation by Klotho in CHO cells (Fig. 4C) . The effect of Klotho on TRPV5 in ST6Gal-1-expressing CHO cells was also prevented by extracellular application of anti-galectin-1 antibodies (Fig.  4D) . Thus, Klotho regulates TRPV5 channels only when they are sialylated via ␣2,6-linkage.
The Golgi enzyme N-acetylglucosaminyltransferase V (GnT-V) catalyzes the addition of ␤1,6-N-acetylglucosamine [GlcNAc␤ (1, 6) ] to the ␣6-mannose producing the tri(2,2,6) and tetra(2,4,2,6) antenarry glycans (27) (Fig. 3A) . The GlcNAc␤(1,6) branch is preferred substrate for addition of poly LacNAc. The affinity of polymeric LacNAc for galectin-1 is much higher than that of LacNAc monomer (22) . Lec4 is a mutant CHO cell line that lacks GnT-V thus containing no cell surface N-linked GlcNAc␤ (1, 6) branches (28) . We found that Klotho increased current density of TRPV5 in Lec4 cells cotransfected with ST6Gal-1 and GnT-V, but not in mock-transfected Lec4 cells, Lec4 cells transfected with ST6Gal-1 alone or with GnT-V alone (Fig. 4E) . Thus, LacNAc or more likely poly LacNAc in the (2,2,6)tri-and/or (2,4,2,6)tetraantenary N-gycans is involved in the enhancement of TRPV5 at the cell surface by Klotho. Although the sialidase from C. perfringens hydrolyzes ␣2,3-linked sialic acids more efficiently, it also hydrolyzes ␣2,6-linked sialic acids at higher concentrations (29) . We asked whether the bacterial sialidase can regulate TRPV5 in CHO cells lacking ST6Gal-1. The bacterial sialidase did not increase TRPV5 in CHO cells (Fig. 4F) . Expression of ST6Gal-1 conferred stimulation by the bacterial sialidase even though it prefers the ␣2,3-linkage. Thus, like Klotho, the bacterial sialidase stimulated TRPV5 channels only when they contained ␣2,6-sialic acids. The concentration of the bacterial sialidase required for increasing TRPV5 currents, however, is 0.1 unit/ml (Ϸ0.2 M), which is Ͼ1,000-fold higher than that of Klotho (see Fig. 1 A and B) . Plant lectins Sambucus nigra agglutinin (SNA) and Maackia amurensis agglutinin (MAA) specifically bind ␣2,6-sialylated and ␣2,3-sialylated glycoconjugates, respectively (30) . We used SNA labeling to examine ␣2,6-sialic acids on TRPV5 and the effect of Klotho to remove these residues. CHO cells were transfected with GFP-TRPV5 or GFP along with ST6Gal-1 or ST3Gal-1 and labeled by fluorescent-attached SNA or MAA. Control untransfected CHO cells were labeled by fluorescent-attached MAA (Fig. 5A) , but not by fluorescent-attached SNA (Fig. 5B) , confirming that they express ST3s but not ST6s, endogenously. In CHO cells cotransfected with GFP-TRPV5 and ST6Gal-1 (Fig. 5 C-F) , SNA labeling (Fig.  5D, red) was detected in almost every transfected cell (Fig. 5C , green) but not in untransfected cells, supporting that expression of ST6Gal-1 produces ␣2,6-sialic acids in CHO cells. Treatment with Klotho markedly reduced SNA labeling in cells cotransfected with GFP-TRPV5 and ST6Gal-1 (Fig. 5 F vs. D; see Fig. S3 for additional images). The specificity of SNA for ␣2,6-sialic acid was further confirmed by the result that transfection with ST3Gal-1 did not give rise to SNA labeling (Fig. 5 G and H) . In contrast, Klotho treatment did not affect SNA labeling in cells cotransfected with GFP and ST6Gal-1 (Fig. 5 I, J, K and M and Fig. S3 ). Note that SNA labeling was less in cells expressing ST6Gal-1 alone (Fig. 5J ) than in cells expressing ST6Gal-1 and channels (Fig. 5D) , likely because, in the absence of ST6Gal-1, its potential substrates are capped by other enzymes (31) . Only transfected ion channels and a fraction of endogenous glycoproteins synthesized during the expression of ST6Gal-1 would be sialylated via ␣2,6-linkage. Klotho treatment did not affect MAA labeling in control CHO cells (data not shown). Thus, Klotho treatment removes ␣2,6-sialic acids from glycan chains of TRPV5, but not from the majority resident surface membrane proteins in CHO cells. For comparison, we found that neither Klotho nor sialidase treatment increases the current density of TRPC6, another TRP channel also present in kidney (data not shown). Our results, however, do not exclude the possibility that Klotho can remove ␣2,6-sialic acids from a subset of GlcNAc ␣(1,6) branch-containing glycoproteins besides TRPV5. 
Discussion
Despite the sequence homology to glycosidases, the physiological role of Klotho as a glycosidase and its endogenous substrate remain elusive. Chang et al. (14) reported that Klotho treatment increases cell-surface abundance of TRPV5 by modifying its N-linked glycans. However, the precise sugar substrates on TRPV5 and how its modification alters the cell-surface abundance are not known. Our present study shows that Klotho participates in removal of ␣2,6-, but not ␣2,3-linked sialic acids, of TRPV5 in intact cells. Removal of terminal sialic acids from N-glycans exposes underlying LacNAc for binding with galectin-1 to enhance retention of TRPV5 at the cell surface (see Fig. 6 ). The interaction of TRPV5 with galectin-1 is likely strengthened by the multiplicity of N-glycans from tetrameric structure of the channel and the presence of polymeric LacNAc, a high-affinity ligand for galectin-1. These results provide an example of glycosidase activity of Klotho acting through a physiologically relevant sugar substrate. It has been reported by Tohyama et al. (32) that Klotho exhibits weak ␤-glucuronidase activity in vitro. Based on the finding that purified bovine liver ␤-glucuronidase also increases TRPV5 activity, Chang et al. (14) concluded that the effect of Klotho on TRPV5 is through hydrolysis of glucuronic acids from TRPV5. However, although glucuronic acids may be sugar moieties of cell-membrane proteins in the form of heparin sulfate proteoglycans (33), they are not common moieties of N-glycans of mammalian cell-surface glycoproteins (27) . To understand the study of Chang et al., we confirmed their finding that purified bovine ␤-glucuronidase increases surface abundance of TRPV5 in HEK cells (data not shown). However, the EC 50 for ␤-glucuronidase regulation of TRPV5 in HEK cells reported by Chang et al. (14) (and in our experiments as well) is Ϸ0.1 M, which is Ϸ2,000-fold higher than that for Klotho (50 pM) observed in this study. The concentration of Klotho in human urine (from where Klotho is expected to regulate TRPV5 localized in the apical membrane of distal renal tubules) (34) is estimated Ϸ20-200 pM (unpublished results). We found that ␤-glucuronidase (0.1-1 M), like Klotho and bacterial sialidase, increased TRPV5 currents only in CHO cells that expressed recombinant ST6Gal-1, but not in control CHO cells (Fig.  S4) . Moreover, we found that knockdown of endogenous ST6Gal-1 by siRNA prevented the increase of TRPV5 currents by ␤-glucuronidase in HEK cells (data not shown). Thus, pharmacological concentrations of ␤-glucuronidase target ␣2,6-linked sialic acids of TRPV5. Indeed, Tohyama et al. (32) have shown that high concentrations of ␤-glucuronidase have off-target enzymatic activities toward other sugar substrates besides glucuronic acids.
Renal Ca 2ϩ reabsorption is decreased in Klotho-deficient mice when compared with WT counterparts (35) , primarily because of decreased Ca 2ϩ entry across the apical membrane of connecting tubules (35) . TRPV5 is the main channel responsible for apical Ca 2ϩ entry in the distal nephron (34) . Thus, the effect to increase cell-surface retention of TRPV5 is important for the regulation of Klotho removes terminal sialic acid from the GlcNAc␤(1,6) branch of (triantenary or) tetra-antenary N-glycan of TRPV5. Removal of sialic acids exposes underlying LacNAc, a ligand for galectin-1. Binding to galectin-1 lattice at the extracellular surface leads to accumulation of functional TRPV5 on the plasma membrane.
